...
首页> 外文期刊>Vox Sanguinis: International Journal of Blood Transfusion and Immunohaematology >Inactivation of severe acute respiratory syndrome coronavirus 2 in plasma and platelet products using a riboflavin and ultraviolet light-based photochemical treatment
【24h】

Inactivation of severe acute respiratory syndrome coronavirus 2 in plasma and platelet products using a riboflavin and ultraviolet light-based photochemical treatment

机译:使用核黄素和紫外线光化学处理血浆和血小板产品中严重急性呼吸综合征冠状病毒2的灭活

获取原文
获取原文并翻译 | 示例

摘要

Background and Objective Severe acute respiratory distress syndrome coronavirus-2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is a member of the coronavirus family. Coronavirus infections in humans are typically associated with respiratory illnesses; however, viral RNA has been isolated in serum from infected patients. Coronaviruses have been identified as a potential low-risk threat to blood safety. The Mirasol Pathogen Reduction Technology (PRT) System utilizes riboflavin and ultraviolet (UV) light to render blood-borne pathogens noninfectious, while maintaining blood product quality. Here, we report on the efficacy of riboflavin and UV light against the pandemic virus SARS-CoV-2 when tested in both plasma and platelets units.
机译:背景与目的严重急性呼吸窘迫综合征冠状病毒-2(SARS-CoV-2)是2019年冠状病毒病(COVID-19)的病原体,是冠状病毒家族的成员。人类冠状病毒感染通常与呼吸道疾病有关;然而,病毒RNA已经从感染患者的血清中分离出来。冠状病毒已被确定为对血液安全的潜在低风险威胁。Mirasol病原体减少技术(PRT)系统利用核黄素和紫外线(UV)使血液传播的病原体不具传染性,同时保持血液制品质量。在这里,我们报告了核黄素和紫外线在血浆和血小板中对大流行病毒SARS-CoV-2的有效性。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号